Product Datasheet

beta-catenin (Phospho-Ser715) Antibody

Catalog No: #11594

Package Size: #11594-1 50ul #11594-2 100ul



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com


_				
	es	\sim rı	nti	\cap r
-	-	OH	่บแ	OI.

Bosciipiioii			
Product Name	beta-catenin (Phospho-Ser715) Antibody		
Host Species	Rabbit		
Clonality	Polyclonal		
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates.		
	Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho		
	specific antibodies were removed by chromatogramphy using non-phosphopeptide.		
Applications	WB IHC		
Species Reactivity	Human;Mouse;Rat		
Specificity	The antibody detects endogenous level of beta-catenin only when phosphorylated at serine 715.		
Immunogen Type	Peptide-KLH		
Immunogen Description	Peptide sequence around phosphorylation site of serine 715 (D-P-S(p)-Y-R) derived from Human		
	beta-catenin.		
Conjugates	Unconjugated		
Target Name	beta-catenin		
Modification	Phospho		
Other Names	Catenin beta-1; CTNB1; CTNNB; CTNNB1		
Accession No.	Swiss-Prot: P35222NCBI Gene ID: 1499		
Target Species	Human		
SDS-PAGE MW	92kd		
Concentration	1.0mg/ml		
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02%		
	sodium azide and 50% glycerol.		
Storage	Store at -20°C		


Application Details

Western blotting: 1:500~1:1000
Immunohistochemistry: 1:50~1:100

Images



Immunohistochemical analysis of paraffin-embedded human primary glioblastoma multiforme (GBM) specimens using beta-catenin (Phospho-Ser715) Antibody #11594.



Western blot analysis of extract from U87 cells transfected with either PKCd siRNA targeting or control siRNA were treated withWnt3a (100 ng ml 1) for 8 h. WB was performed with nuclearlysates of the cells with the beta-catenin (Phospho-Ser715) Antibody #11594.

Background

Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML

Published Papers

Zhimin Lu, Jianfei Xue1, Yaohui Chen, et al. el at., Tumour suppressor TRIM33 targets nuclear b-catenin degradation, NATURE COMMUNICATIONS, DOI: 10.1038/ncomms7156(2015)

PMID:25639486

el at., Tumour suppressor TRIM33 targets nuclear ε[∞]Y-catenin degradation.In Nat Commun on 2015 Feb 2 by Jianfei Xue, Yaohui Chen et al..PMID:25639486, , (2015)

PMID:25639486

Note: This product is for in vitro research use only and is not intended for use in humans or animals.